Navigation Links
Celator in Medical News

Celator(R) Pharmaceuticals Initiates Research Agreement With Cephalon, Inc.

... PRINCETON, N.J., May 21 /PRNewswire/ -- celator Pharmaceuticals today announced that it has entere...tunity to leverage the technology and expertise at celator beyond our own pipeline," said Scott Jackson, chief executive officer, celator Pharmaceuticals. "It is exciting to advance our c...

Celator(R) Pharmaceuticals to Present at 2009 BIO International Convention

... PRINCETON, N.J., May 13 /PRNewswire/ -- celator Pharmaceuticals today announced that Scott Jackson... of the Georgia World Congress Center. About celator Pharmaceuticals, Inc. celator Pharmaceuticals, Inc., with locations in Princeton...

Celator(R) Pharmaceuticals Presents New Data on CPX-351 And CPX-1 at the American Association for Cancer Research

... PRINCETON, N.J., April 22 /PRNewswire/ -- celator Pharmaceuticals today announced that new data from...gms," said Scott Jackson, chief executive officer, celator Pharmaceuticals. "These studies, which further hi...ior studies of CPX-1 as monotherapy. About celator Pharmaceuticals, Inc. ...

Celator(R) Pharmaceuticals to Present at Future Leaders in the Biotech Industry Conference

... PRINCETON, N.J., March 26 /PRNewswire/ -- celator Pharmaceuticals today announced that Scott Jackson...rs and the sponsors of the conference. About celator Pharmaceuticals, Inc. celator Pharmaceuticals, Inc., with locations in Princeton...

Celator(R) Pharmaceuticals Enrolls First Patient in Its Phase 2 Study of CPX-351 in Acute Myeloid Leukemia in First Relapse

...(R) PRINCETON, N.J., March 10 /PRNewswire/ -- celator Pharmaceuticals today announced that the first pat...s," said Scott Jackson, chief executive officer of celator Pharmaceuticals. "There has been increasing excit...y, 9 a.m. to 6 p.m. ET. www.lls.org About celator Pharmaceuticals, Inc. ...

Celator(R) Pharmaceuticals To Present at Biotech Showcase 2009

... PRINCETON, N.J., Jan. 8 /PRNewswire/ -- celator Pharmaceuticals today announced that Scott Jackson...he Marines' Memorial Club & Hotel. About celator Celator(R) Pharmaceuticals, Inc., with location...programs. Based on the applications of CombiPlex, celator is positioned to advance a broad pipeline of combi...

Celator(R) Pharmaceuticals Presents Phase 1 Results With CPX-351 in Patients With Advanced Leukemia at the American Society of Hematology Meeting

...s PRINCETON, N.J., Dec. 9 /PRNewswire/ -- celator Pharmaceuticals today announced that a Phase 1 dos...," said Arthur Louie, MD, chief medical officer at celator Pharmaceuticals. "We began enrolling patients in ...ion," said Scott Jackson, chief executive officer, celator Pharmaceuticals. "We believe this unique capabili...

Frederick R. Appelbaum, M.D. and Ross C. Donehower, M.D. Join Scientific Advisory Board of Celator(R) Pharmaceuticals

...elator. PRINCETON, N.J., Nov. 28 /PRNewswire/ -- celator Pharmaceuticals, a biotechnology company working t...Ratiometric Dosing(TM) process." About Celator celator Pharmaceuticals, Inc., is a privately held biophar... programs. Based on the applications of CombiPlex, celator is positioned to advance a broad pipeline of combi...
Celator in Medical Technology

The Leukemia & Lymphoma Society and Celator Pharmaceuticals Announce Partnership to Accelerate Development of CPX-351 for AML

WHITE PLAINS, N.Y. and PRINCETON, N.J., Jan. 22 /PRNewswire/ -- The Leukemia & Lymphoma Society (LLS) and Celator Pharmaceuticals, Inc. today announced a partnership to support Phase 2 development of Celator's lead product candidate CPX-351 (Cytarabine:Daunorubicin) Liposome Injection for trea...

Celator(R) Pharmaceuticals Announces Enrollment of First Patient in Phase 2 Study with CPX-351

... PRINCETON, N.J., Nov. 18 /PRNewswire/ -- celator Pharmaceuticals today announced that the first pat... "This is an important milestone for celator and we are excited about the benefit CPX-351 may o...s," said Scott Jackson, chief executive officer of celator Pharmaceuticals. "We continue to open new clinica...

Celator Pharmaceuticals Receives Orphan Drug Designation for Anticancer Agent CPX-351

...eukemia PRINCETON, N.J., Sept. 4 /PRNewswire/ -- celator Pharmaceuticals today announced that the U.S. Food...r the treatment of Acute Myeloid Leukemia (AML). celator is currently preparing to conduct two randomized P...y," said Scott Jackson, chief executive officer of celator Pharmaceuticals. "We are committed to developing p...

Celator Pharmaceuticals Raises Series C Financing in Excess of $22.5 Million

... elderly patients with AML before the end of 2008. celator will continue to develop other CombiPlex(TM) produ...s," said Scott Jackson, chief executive officer of celator Pharmaceuticals. "Our goal is to extend and enhanc...h leading biotech and pharmaceutical companies." celator reported encouraging interim Phase 1 data with CPX...

Celator(R) Pharmaceuticals Announces Positive Phase 2 Results for CPX-1 in Treatment of Colorectal Cancer

...al data. PRINCETON, N.J., June 3 /PRNewswire/ -- celator Pharmaceuticals reported positive results from its...etary CombiPlex(TM) technology." About Celator celator Pharmaceuticals, Inc., is a privately held pharmac... programs. Based on the applications of CombiPlex, celator is positioned to advance a broad pipeline of combi...

Celator(R) Pharmaceuticals Successfully Uses Nanoparticles to Administer Hydrophobic Drug Combinations

...seases PRINCETON, N.J., April 16 /PRNewswire/ -- celator Pharmaceuticals today reported results on a novel ...he goal of improving clinical outcomes. To date, celator has utilized liposomes to deliver synergistic drug...from liposomes almost immediately after injection. celator scientists reported that they were able to generat...

Celator(R) Pharmaceuticals Reports CPX-351 Shows Anti-Cancer Activity in Leukemia Patients

...eeting. PRINCETON, N.J., Dec. 10 /PRNewswire/ -- celator Pharmaceuticals today announced results from an on...w Janoff, Ph.D., CEO of Celator. About Celator celator Pharmaceuticals, Inc. is a privately held biopharm... programs. Based on the applications of CombiPlex, celator is positioned to advance a broad pipeline of combi...

Celator Pharmaceuticals Study Shows Anti-Tumor Activity in Cancer Patients Treated with Therapy Based on Ratiometric Dosing

...eviously with irinotecan. Based on these findings, celator is moving forward with a Phase 2 study for CPX-1 t...altrials.gov/ct/show/NCT00361842?order=1 . ABOUT celator celator Pharmaceuticals, Inc., formerly...
Celator in Biological Technology

Celator(R) Pharmaceuticals Presents Data on the Activity of CPX-351 Against Leukemia at the European Hematology Association Congress

... PRINCETON, N.J., June 8 /PRNewswire/ -- celator Pharmaceuticals today announced that new clinical ...ias," said Scott Jackson, chief executive officer, celator Pharmaceuticals. "Our nano-scale liposomal encaps...ficacy and improved therapeutic index. About celator Pharmaceuticals, Inc. ...

Celator(R) Pharmaceuticals to Present at Piper Jaffray Health Care Conference and Mid-Atlantic Capital Conference

... PRINCETON, N.J., Nov. 25 /PRNewswire/ -- celator Pharmaceuticals today announced that Scott Jackson...he Pennsylvania Convention Center About celator celator Pharmaceuticals, Inc., with locations in Princeton...

Celator(R) Pharmaceuticals To Present at 2008 BIO Investor Forum

... PRINCETON, N.J., Oct. 23 /PRNewswire/ -- celator Pharmaceuticals today announced that Scott Jackson... South Room of the Palace Hotel. About Celator celator Pharmaceuticals, Inc., with locations in Princeton... programs. Based on the applications of CombiPlex, celator is positioned to advance a broad pipeline of combi...

Celator(R) Pharmaceuticals to Present at 2008 BIO International Convention

... PRINCETON, N.J., June 16 /PRNewswire/ -- celator Pharmaceuticals today announced that John Bennett,...the San Diego Convention Center. About Celator celator Pharmaceuticals, Inc., is a privately held pharmac... programs. Based on the applications of CombiPlex, celator is positioned to advance a broad pipeline of combi...

Celator(R) Pharmaceuticals Announces Appointment of Scott Jackson as CEO

... PRINCETON, N.J., May 9 /PRNewswire/ -- celator Pharmaceuticals today announced that Scott Jackson...ointed Chief Executive Officer. Mr. Jackson joined celator in October 2007 as Head of Commercial Development....w Janoff. "I'm very excited about the future for celator Pharmaceuticals," said Mr. Jackson. "We have an en...

Celator(R) Pharmaceuticals to Present at 10th Annual BIO CEO and Investor Conference

... PRINCETON, N.J., Feb. 5 /PRNewswire/ -- celator Pharmaceuticals today announced that Andrew Janoff...aldorf-Astoria in New York City. About Celator celator Pharmaceuticals, Inc., is a privately held pharmac... programs. Based on the applications of CombiPlex, celator is positioned to advance a broad pipeline of combi...

Celator(R) Pharmaceuticals Study Shows CPX-571 Maintains Synergistic Ratio of Irinotecan and Cisplatin to Improve Anti-tumor Activity

...al study for third combination chemotherapy from celator based on the company's proprietary ...atform. PRINCETON, N.J., Oct. 26 /PRNewswire/ -- celator Pharmaceuticals today announced positive results f...uie, M.D., Celator's chief medical officer. ABOUT celator ...
Other Tags
(Date:7/25/2014)... The new report “Carbohydrase Market by Applications (Food ... Type (Amylases, Cellulases, and Others), Source (Microorganisms, Animals, ... Forecasts to 2019", by MarketsandMarkets, identifies the driving ... with analysis of trends, opportunities, winning imperatives, and ... forecasted on the basis of major regions such ...
(Date:7/25/2014)... 25, 2014 In today’s technological era, ... and supporting devices. This benefits the organization in various ... cyber attacks which can destroy the confidential information and ... Risk and Compliance (EGRC) manage and protect the enterprise ... can cause loss in dollars to the comp may. ...
(Date:7/25/2014)... NY (PRWEB) July 25, 2014 ... injury law firm with over 25 years of ... stemming from dangerous prescription drugs, announces the launch ... offer information to those who believe they have ... , The site offers valuable information about the ...
(Date:7/25/2014)... The European liquid chromatography reagents report defines ... and forecast of revenue. The liquid chromatography reagents market ... 2013, and is estimated to grow to around $1581.8 ... from 2013 to 2018. , Browse through the TOC ... an idea of the in-depth analysis provided. This also ...
(Date:7/25/2014)... the vast majority of adults finish all of the food ... new study. This is true for adults from ... Cornell University revealed. They noted their findings could help ... make better choices. "If you put it on your ... director of the Cornell Food and Brand Lab, said in ...
Breaking Medicine News(10 mins):Health News:Carbohydrase Market worth $3,717.7 Million by 2019 - Report by MarketsandMarkets 2Health News:Carbohydrase Market worth $3,717.7 Million by 2019 - Report by MarketsandMarkets 3Health News:Carbohydrase Market worth $3,717.7 Million by 2019 - Report by MarketsandMarkets 4Health News:North America Enterprise Governance, Risk, and Compliance Market is Expected to Reach $3,972.6 Million in 2018 - New Report by MicroMarket Monitor 2Health News:North America Enterprise Governance, Risk, and Compliance Market is Expected to Reach $3,972.6 Million in 2018 - New Report by MicroMarket Monitor 3Health News:North America Enterprise Governance, Risk, and Compliance Market is Expected to Reach $3,972.6 Million in 2018 - New Report by MicroMarket Monitor 4Health News:North America Enterprise Governance, Risk, and Compliance Market is Expected to Reach $3,972.6 Million in 2018 - New Report by MicroMarket Monitor 5Health News:North America Enterprise Governance, Risk, and Compliance Market is Expected to Reach $3,972.6 Million in 2018 - New Report by MicroMarket Monitor 6Health News:Rottenstein Law Group LLP Announces Launch of Xarelto Injury Website 2Health News:European Liquid Chromatography Reagents Market is Expected to Reach $1581.8 Million in 2018 - New Report by MicroMarket Monitor 2Health News:European Liquid Chromatography Reagents Market is Expected to Reach $1581.8 Million in 2018 - New Report by MicroMarket Monitor 3Health News:European Liquid Chromatography Reagents Market is Expected to Reach $1581.8 Million in 2018 - New Report by MicroMarket Monitor 4Health News:Most Adults Are Members of 'Clean Plate Club' 2
(Date:7/24/2014)... 24, 2014 -- Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX) (the "Company") ... active control Phase 3 study of Zerenex (ferric citrate), ... the treatment of hyperphosphatemia in patients with end-stage renal ... and iRon delivery with FErric CiTrate in EsrD) was ... American Society of Nephrology ( JASN ). ...
(Date:7/24/2014)... numbers have decreased by 45% on average over a ... reports a study on the impact of humans on ... enormous benefits invertebrates such as insects, spiders, crustaceans, slugs ... and pest control for crops, decomposition for nutrient cycling, ... in Science and led by UCL, Stanford ...
(Date:7/24/2014)... the product of 3.5 billion years of evolutionary trial ... life. But it may be reaching a tipping point. ... analysis of data published in Science , an ... decline of animals is contributing to what appears to ... biological extinction event. , Since 1500, more than 320 ...
Breaking Biology News(10 mins):Zerenex™ (ferric citrate) long-term Phase 3 study results published in JASN 2Zerenex™ (ferric citrate) long-term Phase 3 study results published in JASN 3Zerenex™ (ferric citrate) long-term Phase 3 study results published in JASN 4Invertebrate numbers nearly halve as human population doubles 2Invertebrate numbers nearly halve as human population doubles 3Stanford biologist warns of early stages of Earth's 6th mass extinction event 2Stanford biologist warns of early stages of Earth's 6th mass extinction event 3
Other Contents